Dianthus Therapeutics, Inc. /DE/ Operating Income Loss

• Dianthus Therapeutics, Inc. /DE/ showed a decrease of -74.7% in Operating Income Loss from 2024 to 2025.
• This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Dianthus Therapeutics, Inc. /DE/'s Operating Income Loss has declined by 1,819.9%.
• Historical annual values: Fiscal year 2025: -$177.93 million | Fiscal year 2024: -$101.86 million | Fiscal year 2023: -$48.17 million | Fiscal year 2022: -$29.71 million | Fiscal year 2021: -$74.69 million | Fiscal year 2020: -$78.70 million | Fiscal year 2019: -$82.97 million | Fiscal year 2018: -$59.96 million | Fiscal year 2017: -$35.73 million | Fiscal year 2016: -$9.27 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026